RT Journal Article ID 5d2ca8b772b40307 A1 Hobeika, Amy C. A1 Clay, Timothy M. A1 Mosca, Paul J. A1 Lyerly, H. Kim A1 Morse, Michael A. T1 Quantitating Therapeutically Relevant T-Cell Responses to Cancer Vaccines JF Critical Reviews™ in Immunology JO CRI YR 2001 FD 2001-05-01 VO 21 IS 1-3 OP 11 AB Successful application of active immunotherapy to the treatment of cancer will require stimulation of potent antigen-specific T-cell responses. It is not known how numerous or how potent these T cells must be in order to abrogate tumors, but the levels of immunity needed to control chronic viral infections may provide estimates for comparison. Evaluation of the efficacy of a vaccine strategy in attaining these levels of immunity will depend on the use of assays that create a picture of T-cell number and function that correlates with clinical outcomes. We discuss the currently available in vivo and in vitro T-cell assays and their relevance for detecting therapeutic levels of T-cell activity. We also propose a strategy for efficiently evaluating the immunologic efficacy of cancer vaccines so that the most promising candidates can be brought more rapidly into definitive clinical trials. PB Begell House LK https://www.dl.begellhouse.com/journals/2ff21abf44b19838,46f5c0d0074d488c,5d2ca8b772b40307.html